Visual Performance of Dailies Total1 Multifocal and Acuvue Oasys Max 1-Day Multifocal in Presbyopic Lens Wearers

Last updated: December 4, 2024
Sponsor: University of Waterloo
Overall Status: Completed

Phase

N/A

Condition

Presbyopia

Treatment

Deleficon A (multifocal)

Senofilcon A (multifocal)

Clinical Study ID

NCT06369987
46238
  • Ages > 42
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to measure the logMAR visual acuity when presbyopic soft lens wearers are fit with Dailies Total1 Multifocal and ACUVUE OASYS MAX 1-DAY Multifocal.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Are at least 42 years of age and has full legal capacity to volunteer;

  2. Have signed an information consent letter;

  3. Are willing and able to follow instructions and maintain the appointment schedule;

  4. Habitually wears soft contact lenses for the past 3 months (minimum);

  5. Are presbyopic and require a reading addition of at least +0.75D and no more than +1.75D;

  6. Can be refracted and achieve monocular spectacle distance vision of at least 20/25Snellen (or +0.10logMAR) visual acuity;

  7. Have contact lens power requirements that fall within the available study lensparameters (distance sphere: +6D to -9D; near addition as per each lens design);

  8. Can be fit with the initial fitting guidelines provided by the lens manufacturer anduse either Low or Medium Add (same add in both eyes).

Exclusion

Exclusion Criteria:

  1. Are a current habitual wearer of Dailies Total1 Multifocal or ACUVUE OASYS MAX 1-DAYMultifocal;

  2. Has refractive astigmatism higher than -0.75DC in either eye;

  3. Are participating in any concurrent clinical or research study involvingintervention or invasive ocular tests;

  4. Have any known active ocular disease and/or infection;

  5. Has a systemic condition that in the opinion of the investigator may affect a studyoutcome variable;

  6. Are using any systemic or topical medications that in the opinion of theinvestigator may affect a study outcome variable;

  7. Have known sensitivity to the diagnostic pharmaceuticals to be used in the study;

  8. Have undergone refractive error surgery;

  9. Are a member of the Centre for Ocular Research & Education (CORE) directly involvedin the study.

Study Design

Total Participants: 28
Treatment Group(s): 2
Primary Treatment: Deleficon A (multifocal)
Phase:
Study Start date:
April 25, 2024
Estimated Completion Date:
November 21, 2024

Connect with a study center

  • Centre for Ocular Research & Education (CORE)

    Waterloo, Ontario N2L 3G1
    Canada

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.